Investor Presentaiton

R&D Highlights Immunology and Neurology Haematology and Thrombosis . Respiratory Cardiovascular and Metabolic ✗ Transplant Influenza Vaccines • 15 Driven by Our Promise™ HIZENTRAⓇ granted Orphan Drug Exclusivity for CIDP HIZENTRAⓇ Dermatomyositis (DM) Phase III Study initiated Garadacimab (Anti-FXIIa) in Hereditary Angioedema (HAE) Phase II double blind period complete • CSL200 (CAL-H) in Sickle Cell Disease (SCD) Phase I Study initiated • CSL889 Hemopexin in SCD Phase I Study initiated • • CSL311 (Anti-Beta Common) Phase I study commenced Approval of convenient single-vial dosing for ZEMAIRAⓇ (Alpha1-Proteinase Inhibitor) in the US © CSL112 (ApoA-1) Phase III study (AEGIS-II) progressing well with >7000 patients recruited . CSL964 Alpha-1 Antitrypsin (AAT) for prevention of Graft versus Host Disease (GVHD) after Transplantation of Allogenic Hematopoietic Cell Transplantation (HCT) Phase III study actively recruiting and on track • First cell-based quadrivalent seasonal influenza vaccine, FLUCELVAX® TETRA, approved in Europe • AFLURIA® QUAD (quadrivalent influenza vaccine) granted expanded indication for use in children 6M+ in Australia ⚫aQIVC (MF59 plus FLUCELVAXⓇ antigen) new product development commenced CSL

View entire presentation